Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives

BACKGROUND: The IMpower110 trial revealed that atezolizumab treatment had significantly longer overall survival (OS) than chemotherapy in non-small cell lung cancer (NSCLC) patients with high-programmed death ligand 1 (PD-L1) expression. The purpose of the present study was to estimate the cost-effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Shuqiao, Pei, Rui, Li, Jianhuang, Li, Bin, Tang, Lanhua, Yin, Tao, Liu, Shao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506791/
https://www.ncbi.nlm.nih.gov/pubmed/34734033
http://dx.doi.org/10.21037/atm-21-4294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506791/
https://www.ncbi.nlm.nih.gov/pubmed/34734033
http://dx.doi.org/10.21037/atm-21-4294

Ejemplares similares